ZYNE - Zynerba Pharmaceuticals Inc
Close
1.3
0.030 2.308%
Share volume: 0
Last Updated: Tue 10 Oct 2023 10:00:00 PM CEST
Pharmaceutical Preparation Manufacturing :
-2.88%
PREVIOUS CLOSE
CHG
CHG%
$1.27
0.03
2.36%
Summary score
45%
Profitability
50%
Dept financing
3%
Liquidity
50%
Performance
50%
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Long-term ratios 30-Jun-2016 - 30-Jun-2020
The data are presented for the financials results of the quarters of the last 4 years.
Return on equity
-16.02%
Return on assets
-13.95%
Return on sales
0%
Return on invested capital
125.31%
Total debt ratio
13.37%
Debt ratio change over timeo
-0.86%
Current Ratio
8.04%
Quick Ratio
0%
Cash Position Ratio
7.09%
Short-term ratios 30-Jun-2019 - 30-Jun-2020
The data are presented for the financials results of the quarters of the last year.
Return on equity
-14.59%
Return on assets
-13.34%
Return on sales
0%
Return on invested capital
101.59%
Total debt ratio
12.88%
Debt ratio change over timeo
-0.72%
Current Ratio
7.94%
Quick Ratio
0%
Cash Position Ratio
6.68%
Last quarter ratios 30-Jun-2020
The data are presented for the financials results of the last quarter.
Return on equity
-27.32%
Return on assets
-24.97%
Return on sales
0%
Return on invested capital
186.31%
Total debt ratio
14.92%
Debt ratio change over time
-0.84%
Current Ratio
6.54%
Quick Ratio
0%
Cash Position Ratio
5.9%
Performance ratios (change over 4 years) 30-Jun-2016 - 30-Jun-2020
The data are presented for the change financials results of the quarter of the last 4 years.
Return on equity
-116.52%
Return on assets
-114.69%
Return on sales
0%
Return on invested capital
28.67%
Total debt ratio
-85.73%
Debt ratio change over time
-0.86%
Current Ratio
7.65%
Quick Ratio
0%
Cash Position Ratio
6.38%
Compare in sector
The following table compares the individual analyzes for the other top 3 stocks within the same industry.
| Long-term ratios | ZYNE | VLON | ELAT | RETA |
|---|---|---|---|---|
| Return on equity | -16.02% | 0% | 0% | 29.06% |
| Return on assets | -13.95% | 0% | 0% | -9.75% |
| Return on sales | 0% | 0% | 0% | -1469.44% |
| Return on invested capital | 125.31% | 0% | 0% | 47.78% |
| Profitability | 50% | 0% | 25% | 35% |
| Total debt ratio | 13.37% | 0% | 0% | 183.15% |
| Debt ratio change over time | -0.86% | 0% | 0% | 19.02% |
| Dept financing | 2% | 0% | 0% | 50% |
| Current Ratio | 7.94% | 0% | 0% | 5.9% |
| Quick Ratio | 0% | 0% | 0% | 5.9% |
| Cash Position Ratio | 6.68% | 0% | 0% | 5.68% |
| Liquididy | 50% | 0% | 0% | 51% |
| Short-term ratios | ZYNE | VLON | ELAT | RETA |
|---|---|---|---|---|
| Return on equity | -14.59% | 0% | 0% | -16.12% |
| Return on assets | -13.34% | 0% | 0% | -14.95% |
| Return on sales | 0% | 0% | 0% | -3498.94% |
| Return on invested capital | 101.59% | 0% | 0% | 96.56% |
| Profitability | 50% | 0% | 50% | 24% |
| Total debt ratio | 12.88% | 0% | 0% | 79.61% |
| Debt ratio change over time | -0.72% | 0% | 0% | 0.09% |
| Dept financing | 4% | 0% | 0% | 50% |
| Current Ratio | 7.94% | 0% | 0% | 5.9% |
| Quick Ratio | 0% | 0% | 0% | 5.9% |
| Cash Position Ratio | 6.68% | 0% | 0% | 5.68% |
| Liquididy | 50% | 0% | 0% | 65% |